Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche OTC Business Review Raises Questions On Xenical Switch

This article was originally published in The Tan Sheet

Executive Summary

Roche's decision to put its nonprescription business under review may indicate that a switch of its anti-obesity drug Xenical is unlikely

You may also be interested in...



Roche Has Many Suitors For $1.4 Bil. OTC Unit

A GlaxoSmithKline/Roche consumer unit combination would have approximately $7.56 bil. in annual sales

Roche Has Many Suitors For $1.4 Bil. OTC Unit

A GlaxoSmithKline/Roche consumer unit combination would have approximately $7.56 bil. in annual sales

Roche Has Many Suitors For $1.4 Bil. OTC Unit

A GlaxoSmithKline/Roche consumer unit combination would have approximately $7.56 bil. in annual sales

Related Content

Topics

UsernamePublicRestriction

Register

PS096464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel